Basal Cell Carcinoma Market

Market Overview:

The 7 major basal cell carcinoma markets reached a value of US$ 5.2 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 9.3 Billion by 2034, exhibiting a growth rate (CAGR) of 5.31% during 2024-2034.

The basal cell carcinoma market has been comprehensively analyzed in IMARC's new report titled "Basal Cell Carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Basal cell carcinoma (BCC) refers to a non-melanocytic skin cancer that arises from basal cells located in the lower layer of the epidermis. It is often characterized by a painless raised area of skin, which may be shiny with ulcerations or tiny blood vessels running over it. BCC is an aggressive illness that can destroy the tissues around it, causing severe complications like disfigurement. The common symptoms associated with this disease include skin lesions, redness, a small bump, loss of color, scaly patches, swollen blood vessels in the skin, nodules, a waxy, hard skin growth, etc. In some cases, patients also experience itchiness and oozing. The diagnosis of BCC is typically made by reviewing the patient's symptoms, medical history, and physical tests. Further, a skin biopsy, which involves the removal of tiny samples of the affected skin lesion to examine it under a high-powered microscope, is required to confirm a diagnosis. The healthcare provider may also perform a CT or MRI scan to visualize cancer in the lymph nodes or internal organs.

The increasing cases of overexposure to ultraviolet rays from the sun that can damage DNA in the skin cells are primarily driving the basal cell carcinoma market. In addition to this, the rising incidences of several associated risk factors, including advancing age, fairer skin, chronic infections, family history of cancer, etc., are also bolstering the market growth. Furthermore, the widespread adoption of hedgehog pathway inhibitors, such as sonidegib and vismodegib, for treating locally advanced or metastatic disease conditions is acting as another significant growth-inducing factor. These medications inhibit a transmembrane protein required for Hedgehog signal transduction, thereby restricting tumor growth and preventing its recurrence in patients. Additionally, the escalating demand for cryotherapy, which uses liquid nitrogen to freeze and destroy tumor cells and ultimately improve overall survival, is further creating a positive outlook for the market. Apart from this, the emerging popularity of programmed death receptor-1 blocking antibodies, including cemiplimab, over traditional treatment options on account of their improved efficacy and safety profiles is expected to drive the basal cell carcinoma market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the basal cell carcinoma market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for basal cell carcinoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the basal cell carcinoma market in any manner.

Recent Developments:

• In January 2024, Verrica Pharmaceuticals Inc. announced that the final patient had been dosed in Part 2 of the Phase 2 trial of VP-315, a potential first-in-class oncolytic peptide for the treatment of basal cell carcinoma.
• In December 2023, AiViva Biopharma Inc. reported the completion of first trial, which administered AIV001 (axitinib) to patients with basal cell carcinoma tumors. AIV001 is AiViva's innovative intradermal product developed to provide localized, long-term treatment for dermatological diseases.
• In August 2023, Biofrontera Inc. reported that patient recruitment is now completed in the Phase 3 clinical research assessing Ameluz-PDT in combination with the BF-RhodoLED light for the treatment of basal cell carcinoma.
• In July 2023, MediWound Ltd. revealed favorable results from its Phase I/II study to assess the safety and efficacy of MW005 in the treatment of low-risk basal cell carcinoma. The data suggest that MW005 is safe and well tolerated, with patients achieving total clinical and histological clearance of their target lesions.

Key Highlights:

• Basal cell carcinoma is the most prevalent cutaneous cancer, affecting almost one in every five Americans.
• BCC is highly common in White populations; it is quite rare in those with darker-colored skin.
• In White populations in the U.S., the incidence of BCC has risen by more than 10% every year, with a lifetime risk of having a BCC of 30%.
• BCC rates are often higher in men than in women.
• BCC incidence rates rise with age, with a median diagnostic age of 68 years.

Drugs:

Imiquimod is a PBS-subsidized immune response modulator used to treat superficial basal cell carcinoma that has been proven by biopsy. Imiquimod may be effective when surgery is contraindicated for patients who are willing and capable of following the 6-week course of medication.

EscharEx is a bioactive, multimodal debridement therapy that may be used topically and is currently in advanced clinical trials. The candidate removes eschar (dry, dead tissue) from the wounds. The mechanism of action is mediated by proteolytic enzymes that break and eliminate necrotic tissue, preparing the wound bed for healing.

AIV-001 is under development by AiViva BioPharma for the treatment of low-risk basal cell carcinoma. The medication candidate is produced as a suspension and delivered via the intradermal method for wound healing.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the basal cell carcinoma market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the basal cell carcinoma market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current basal cell carcinoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the basal cell carcinoma market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the basal cell carcinoma market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the basal cell carcinoma market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of basal cell carcinoma across the seven major markets?
• What is the number of prevalent cases (2018-2034) of basal cell carcinoma by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of basal cell carcinoma by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with basal cell carcinoma across the seven major markets?
• What is the size of the basal cell carcinoma patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of basal cell carcinoma?
• What will be the growth rate of patients across the seven major markets?
   

Basal Cell Carcinoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for basal cell carcinoma drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the basal cell carcinoma market?
• What are the key regulatory events related to the basal cell carcinoma market?
• What is the structure of clinical trial landscape by status related to the basal cell carcinoma market?
• What is the structure of clinical trial landscape by phase related to the basal cell carcinoma market?
• What is the structure of clinical trial landscape by route of administration related to the basal cell carcinoma market?